* There is currently no vaccine or antiviral treatment for ZIKV, but research is focusing on the viral NS2B/NS3 protease as a potential target for new antiviral drugs.
* Studies show that the unlinked form of ZIKV protease is more active and binds to substrates more effectively than the linked form, suggesting that it should be prioritized in the development of ZIKV protease inhibitors.